About Symetis
Symetis is a Healthcare company based in Ecublens (Switzerland) founded in 2001, and was acquired by Boston Scientific in March 2017. It operates as a minimally invasive heart valve replacement devices are developed and marketed. Symetis has raised $56.66 million across 3 funding rounds from investors including Boston Scientific, Truffle Capital and Endeavour Vision. Symetis has completed 1 acquisition, including Middle Peak Medical. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its competitors include Shockwave Medical, Cardiac Dimensions, Venus MedTech, Pi-Cardia and Peijia Medical Technologies and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Symetis was founded in 2001 in Ecublens, Switzerland, within the medical devices sector focused on cardiac therapies. Minimally invasive replacement options for heart valve diseases are developed, including proprietary Acurate TA and Acurate neo systems with delivery mechanisms. These products are marketed across Europe and select international markets. Manufacturing operations are conducted in facilities located in Brazil and Switzerland. A planned initial public offering was suspended in late 2015.
- Headquarters Ecublens, Switzerland
- SectorsHealthcare
- Website symetis.com
- Social LinkedIn
- Acquired by Boston Scientific (Mar 2017)
- Total Equity Funding$56.66M (USD)
in 3 rounds
- Latest Funding Round$25.8M (USD), Series C
Oct 2010
- InvestorsBoston Scientific
& 11 more
- Investments & Acquisitions
- Acquired byBoston Scientific
(Mar 2017)
Funding Insights of Symetis
Symetis has successfully raised a total of $56.66M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $25.8 million completed in October 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $56.66M
- Total Rounds 3
- Last Round Series C — $25.8M
- First Round $9.6M
(Oct 2004)
- Investors Count 11
All 3 funding rounds of Symetis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2010 | $25.8M | Series C | – | Endeavour Vision | |
| Jul 2009 | $21.26M | Series B | – | Wellington Partners Venture Capital, Renaissance | |
| Oct 2004 | $9.6M | Series A | – | Truffle Capital, Aravis |
12 investors in total: 12 institutional.
Investors in Symetis
Symetis has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Boston Scientific, Truffle Capital and Endeavour Vision.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Endeavour Vision is focused on transformative healthcare technology investments. | – | endeavourvision.com | Geneva, Switzerland | |
Truffle Capital is recognized as a leading European venture capital firm. | 2001 | truffle.com | Paris, France | |
Investments are made in innovative life science companies globally. | – | nvfund.com | Basel, Switzerland | |
Investments are made in early-stage healthcare startups. | – | wellington-partners.com | Munich, Germany | |
- | – | biomedinvestors.com | - | |
Kreaxi is engaged in equity financing for innovative startups. | – | kreaxi.com | Limonest, France | |
Stage Capital is focused on private equity investments. | – | stagecap.com | London, United Kingdom | |
Early to mid stage life sciences-focused VC firm investing in geographies such as Europe | – | biomedvc.com | Basel, Switzerland | |
Growth capital is provided by Aravis for Swiss high-tech companies. | – | aravis.ch | Switzerland | |
Investments are made in Swiss SMEs for succession and growth. | 1997 | renaissance.net | Lausanne, Switzerland |
Investor details for Symetis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Symetis
Symetis has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Middle Peak Medical.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Mitral valve disease implant technology is developed for cardiac interventions. | middlepeakmedical.com | Palo Alto, United States | 2011 | Feb 2017 | •••• |
Complete acquisition details for Symetis
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Symetis
5 dated milestones of Symetis across 16 years, from founding to its latest funding, stage changes and deals.
- Founded Symetis is founded.
- Funding First funding round of $9.6M.
- Funding Latest funding round, Series C, of $25.8M.
- Acquisition Acquires Middle Peak Medical.
- Exit Acquired by Boston Scientific.
Competitors of Symetis
Symetis has 9 listed competitors in our database, 9 of them funded. They include Shockwave Medical, Cardiac Dimensions, Venus MedTech, Pi-Cardia and Peijia Medical Technologies, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| shockwavemedical.com | 2009 | Santa Clara, United States | $147.5M | 1,394 | Cardiovascular balloon dilation catheters with lithotripsy electrodes are developed. | |
| cardiacdimensions.com | 2001 | Kirkland, United States | $260.8M | 31 | Invasive cardiac implants for heart failure treatment are developed. | |
| venusmedtech.com | 2009 | Hangzhou, China | $37M | – | Transcatheter aortic and pulmonic valves are developed for cardiovascular procedures. | |
| pi-cardia.net | 2009 | Rehovot, Israel | $40M | – | Non-implant devices for cardiac valve repair are developed and manufactured. | |
| peijiamedical.com | 2012 | Suzhou, China | $110.08M | – | Medical devices for cardiac and cerebrovascular treatments are developed. | |
| jenavalve.com | 2006 | Irvine, United States | $363.7M | 198 | Pericardial transcatheter aortic valve replacement systems are provided. | |
| neochord.com | 2007 | Eden Prairie, United States | $108.67M | 7 | Minimally invasive mitral valve repair devices are developed and provided. | |
| tricares.com | 2013 | Aschheim, Germany | $102.84M | – | Minimally invasive tricuspid valve replacement system is developed. | |
| capstanmedical.com | 2020 | Santa Cruz, United States | $141.4M | – | Medical devices for structural heart disease treatment are developed. |
Detailed competitors of Symetis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
10 companies that operate in the same segment as Symetis (Cardiac and Vascular Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Connected devices for health, sleep, and activity monitoring are developed. | 2008 | Moulineaux, Seine-maritime, France | USD 93.83 M | – | – | |
SMT is recognized as a developer of cardiovascular medical devices. | 1998 | Surat, Gujarat, India | – | USD 106.25 M | 1,090 | |
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | – | 255 | |
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 | |
Cloud-based ambulatory ECG monitors for cardiac arrhythmia diagnosis are provided. | 2006 | San Francisco, California, United States | USD 109.23 M | USD 747.14 M | 2,000 | |
Provider of neuroprotection devices for carotid artery disease | 2007 | Sunnyvale, California, United States | USD 241.8 M | – | – | |
Miniaturized wireless implantable sensors are developed for hemodynamic monitoring. | 2007 | East Peoria, Illinois, United States | USD 154.77 M | – | 104 | |
Access catheters for neurovascular stroke treatment are provided. | 2015 | Campbell, California, United States | USD 596 M | – | – | |
Biosensor patches are developed for monitoring multiple body vitals. | 2011 | Campbell, California, United States | USD 239.95 M | – | 184 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Symetis
Complete news archive for Symetis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Symetis
Symetis was founded in 2001 and raised its 1st funding round 3 years after it was founded.
Symetis is headquartered in Ecublens, Switzerland. It is registered at Ecublens, Vaud, Switzerland.
Symetis is a funded company, having raised a total of $56.66M across 3 funding rounds to date. The company's 1st funding round was a Series A of $9.6M, raised on Oct 2004.
Symetis was founded in 2001 in Ecublens, Switzerland, within the medical devices sector focused on cardiac therapies. Minimally invasive replacement options for heart valve diseases are developed, including proprietary Acurate TA and Acurate neo systems with delivery mechanisms. These products are marketed across Europe and select international markets. Manufacturing operations are conducted in facilities located in Brazil and Switzerland. A planned initial public offering was suspended in late 2015.
Symetis's top competitors include Shockwave Medical, Cardiac Dimensions and JenaValve Technology.
Symetis has made 1 acquisition, including Middle Peak Medical.
Symetis has 12 investors. Key investors include Boston Scientific, Truffle Capital, Endeavour Vision, Novartis Venture Fund, and Wellington Partners Venture Capital.
Yes. Symetis was acquired by Boston Scientific in March 2017.